Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differences between clinical trials and postmarketing use.

Karin Martin1, Bernard Bégaud, Philippe Latry

  • 1Département de Pharmacologie, Université Victor Segalen, Bordeaux 2, Bordeaux, France. karin.martin@pharmaco.u-bordeaux2.fr

British Journal of Clinical Pharmacology
|December 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiplexing antibiotic screening assay in droplet microfluidics.

Scientific reports·2026
Same author

Serious respiratory distress associated with bosentan administration in chronic thromboembolic pulmonary hypertension: A case report.

Therapie·2026
Same author

"It's like a reverse Robin Hood-We all know they can't pay": How court actors navigate the logics of monetary sanctions.

Criminology : an interdisciplinary journal·2025
Same author

Focusing on family finances reveals actual cost of incarceration.

Science advances·2025
Same author

A droplet microfluidic strategy for cultivation, investigation, and high-throughput isolation of mouse gut microbiome bacteria.

Applied and environmental microbiology·2025
Same author

Advancing droplet-based microbiological assays: optofluidic detection meets multiplexed droplet generation.

The Analyst·2025
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
See all related articles

Clinical trials do not fully represent real-world patient populations, leading to potential differences in drug effectiveness and safety. Postmarketing studies are crucial for assessing the relevance of premarketing data in diverse patient groups.

Area of Science:

  • Pharmacovigilance
  • Clinical Trial Design
  • Real-World Evidence

Background:

  • Clinical trials are the benchmark for drug efficacy and safety.
  • Standardized trial conditions may differ significantly from real-world prescription and use.
  • Discrepancies in patient selection and treatment can impact actual drug outcomes.

Purpose of the Study:

  • To compare patient characteristics and treatment patterns between clinical trials and postmarketing settings.
  • To analyze the potential consequences of these differences on drug efficacy and safety.
  • To highlight the need for real-world data to complement premarketing studies.

Main Methods:

  • Comparative analysis of demographic characteristics and treatment patterns.
  • Examination of data from clinical trials versus postmarketing populations.

Related Experiment Videos

  • Focus on three example drugs: tacrine, celecoxib, and simvastatin.

    • Main Results:

    • Significant differences observed in patient populations and treatment patterns across studied drugs.
    • Confirmation of under-representation of women and elderly patients in clinical trials.
    • Clinical trial protocols imposed highly restrictive criteria on concomitant medication use compared to real-world settings.

    Conclusions:

    • Premarketing clinical trial data may not fully reflect real-world drug performance.
    • Observational postmarketing studies are essential for validating premarketing findings.
    • Systematic postmarketing surveillance is recommended for novel and expensive medications.